Sotorasib plus panitumumab may be a promising treatment option for colorectal cancer
1. While not statistically significant, the use of sotorasib plus panitumumab may have a 30% relative risk reduction in the ...
Tag: oncology
Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer:
1. The highest-ranking phenotypic predictors of head and neck cancer included past tobacco smoking, job code at baseline, pain experienced ...
Imlunestrant extends progression-free survival in ER-positive, HER2-negative breast cancer
1. In this randomized controlled trial, in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced ...
2 Minute Medicine Rewind April 7, 2025
Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer: A UK Biobank study 1. The highest-ranking phenotypic ...
#VisualAbstract Lack of sentinel-lymph node biopsy does not alter survival in early invasive breast cancer
1. In this randomized, non-inferiority trial, the omission of surgical axillary staging was noninferior to sentinel lymph node biopsy in patients ...
Venetoclax plus azacitidine demonstrating efficacy for high-risk myelodysplastic syndromes
1. In patients with treatment-naive high-risk myelodysplastic syndromes (HR MDS), the use of venetoclax (14 days) plus azacitidine was well ...
Lack of sentinel-lymph node biopsy does not alter survival in early invasive breast cancer
1. In this randomized, non-inferiority trial, the omission of surgical axillary staging was noninferior to sentinel lymph node biopsy in ...
Lenvatinib plus pembrolizumab not associated with improved survival compared to standard therapy for recurrent endometrial cancer
1. In patients with advanced or recurrent endometrial cancer (EC) with previous exposure to carboplatin and paclitaxel (PT), lenvatinib plus ...
2 Minute Medicine Rewind March 17, 2025
Clinical Outcomes of Hypertonic Saline vs Mannitol Treatment Among Children With Traumatic Brain Injury 1. Compared with the use of ...
Durvalumab and bevacizumab plus chemoembolization improves progression-free survival in hepatocellular carcinoma
1. Progression-free survival was significantly greater in the durvalumab plus bevacizumab group compared to placebo. 2. Common treatment-related adverse events ...